FDA approves Merck’s ZINPLAVA™ (bezlotoxumab) to reduce recurrence of CDI
Merck announced the FDA has approved ZINPLAVA™ (bezlotoxumab) Injection. Merck anticipates making ZINPLAVA available in first quarter 2017.
ZINPLAVA is indicated to reduce recurrence of Clostridium difficile infection in patients 18 years of age or older receiving antibacterial drug treatment. October 21, 2016